###begin article-title 0
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities
###end article-title 0
###begin p 1
###xml 112 133 112 133 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mal@mrc-lmb.cam.ac.uk</email>
Correspondence may also be addressed to Marc-Andre Langlois. Tel: +44 1223 402269; Fax: +44 1223 412178; Email: mal@mrc-lmb.cam.ac.uk
###end p 1
###begin p 2
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
###end p 2
###begin p 3
###xml 606 642 606 642 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">journals.permissions@oupjournals.org</email>
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
###end p 3
###begin p 4
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 100 105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 206 211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 514 519 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human APOBEC3F and APOBEC3G are double-domained deaminases that can catalyze dC-->dU deamination in HIV-1 and MLV retroviral DNA replication intermediates, targeting T-C or C-C dinucleotides, respectively. HIV-1 antagonizes their action through its vif gene product, which has been shown (at least in the case of APOBEC3G) to interact with the N-terminal domain of the deaminase, triggering its degradation. Here, we compare APOBEC3F and APOBEC3G to APOBEC3C, a single-domained deaminase that can also act on both HIV-1 and MLV. We find that whereas APOBEC3C contains all the information necessary for both Vif-binding and cytidine deaminase activity in a single domain, it is the C-terminal domain of APOBEC3F and APOBEC3G that confer their target site specificity for cytidine deamination. We have exploited the fact that APOBEC3C, whilst highly homologous to the C-terminal domain of APOBEC3F, exhibits a distinct target site specificity (preferring Y-C dinucleotides) in order to identify residues in APOBEC3F that might affect its target site specificity. We find that this specificity can be altered by single amino acid substitutions at several distinct positions, suggesting that the strong dependence of APOBEC3-mediated deoxycytidine deamination on the 5'-flanking nucleotide is sensitive to relatively subtle changes in the APOBEC3 structure. The approach has allowed the isolation of APOBEC3 DNA mutators that exhibit novel target site preferences.
###end p 4
###begin title 5
INTRODUCTION
###end title 5
###begin p 6
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 1108 1110 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 160 165 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 194 199 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 578 583 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 776 781 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G (which has also been named CEM15) was discovered as an element capable of restricting infection of the non-permissive T-cell line CEM by Vif-deficient HIV-1 particles (1). In wild-type HIV-1, the virus-encoded Vif protein counteracts the anti-viral effect of APOBEC3G by inducing its poly-ubiquitination and subsequent proteasome-mediated degradation (2-6). An aspartic acid residue in the first domain of human APOBEC3G (position 128) is critical for the interaction with and sensitivity to Vif (7-10). In the absence of a Vif-interaction, APOBEC3G is encapsidated in HIV-1 [and can similarly be encapsidated by Moloney leukemia virus (MLV)] through binding to the retroviral gag polypeptide and, more specifically, to the nucleocapsid-forming region in the case of HIV-1 (11-15). The APOBEC3G protein that has been incorporated into the virion then acts in the target cell to deaminate deoxycytidines (dC) in the minus-strand retroviral cDNA replication intermediate (16-20). This deamination is not random: dC residues targeted by APOBEC3G are nearly always preceded by a 5'-dC residue (16,17,21,22).
###end p 6
###begin p 7
###xml 71 79 71 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 480 482 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 483 485 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 956 958 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 959 961 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 281 286 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 473 478 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 578 583 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 666 671 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 897 902 <span type="species:ncbi:9606">human</span>
###xml 949 954 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Whilst evidence of retroviral restriction by APOBEC3G largely rests on in vitro co-transfection assays carried out with artificial retroviral constructs, support for the idea that host-mediated deamination of retroviral replication intermediates can actually occur during clinical HIV-1 infection is indicated by the observation that tonic G-->A hypermutation (that can be ascribed to dC-->dU deamination of minus-strand cDNA) is frequently observed in natural isolates of HIV-1 (23-27). However, the pattern of G-->A substitutions exhibited by naturally occurring hypermutated HIV-1 sequences indicates that APOBEC3G is not the only cytidine deaminase that attacks HIV-1. Hypermutation is observed at both GG and GA dinucleotides in the retroviral genome consistent with deamination of both TC and CC dinucleotides in minus-strand cDNA. Indeed, recent work has revealed that other members of the human APOBEC3 family apart from APOBEC3G can act on HIV-1 (28-33).
###end p 7
###begin p 8
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 271 276 271 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">24&#8211;30</sub>
###xml 266 282 266 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HXE-X<sub>24&#8211;30</sub>-PCXXC</italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.coli</italic>
###xml 417 419 417 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 315 321 <span type="species:ncbi:562">E.coli</span>
The human APOBEC3 family of cytidine deaminases comprises seven genes (A to D and F to H) that are encoded in a cluster located on chromosome 22 (34-37). In all cases, they contain either one or two copies of a core motif that is typical to all cytidine deaminases: HXE-X24-30-PCXXC (34,38-40). Previous studies on E.coli cytidine deaminase (ECCDA) propose that the histidine and two cysteines in this motif enable Zn2+ coordination, whilst the glutamate serves as a proton donor in the deamination process (41-43). Whereas APOBEC3A, C and H have but a single zinc binding domain, APOBEC3B, -D, -F and -G are double-domained proteins, containing two copies of the zinc-coordination motif. Although the double-domained APOBEC3G is the most studied of these deaminases, it has not yet been fully resolved as to whether one of its two deaminase domains plays a dominant role in retroviral restriction/deamination (17,20,44).
###end p 8
###begin p 9
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 147 152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recent evidence has now revealed that, in addition to APOBEC3G, the double-domained deaminases APOBEC3B and APOBEC3F can also be incorporated into HIV-1 virions and deaminate retroviral minus-strand cDNA (28-31,33). Indeed, their mutation spectra could account for much, if not all, of the hypermutation seen at TC dinucleotides (28-31,33).
###end p 9
###begin p 10
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 309 314 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 504 507 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 659 664 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
With regard to single domained APOBEC3's, we have previously shown that human APOBEC3C (which is highly homologous to the second domain of human APOBEC3F) is capable of deaminating dC in DNA as judged by a bacterial mutation assay (21). Whilst APOBEC3C did not exhibit any strong restricting activity against HIV-1 or MLV in earlier comparisons of the anti-retroviral activity of APOBEC3 family members (28-31,33), recent results from Yu et al. (29) reveal that APOBEC3C can act as a potent inhibitor of SIV inhibition. In fact, we find that whilst APOBEC3C is certainly less potent than APOBEC3F and APOBEC3G, it can clearly act to deaminate MLV (as well as HIV-1) retroviral replication intermediates, with a characteristic target site preference. This has allowed us to use an MLV-based assay to perform a mutagenesis and domain-swap comparison of APOBEC3C and APOBEC3F that give insight into amino acid residues that affect their target site specificity.
###end p 10
###begin title 11
MATERIALS AND METHODS
###end title 11
###begin title 12
Cells and vectors
###end title 12
###begin p 13
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 1186 1187 1182 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 1188 1190 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1330 1331 1322 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 161 165 <span type="species:ncbi:9913">calf</span>
###xml 556 561 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 642 647 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 768 773 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 828 832 <span type="species:ncbi:11819?1.0">SFFV</span>
###xml 857 862 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1246 1249 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The CEM-SS cell line was obtained from the National Institute for Biological Standards and Control, Herts, UK and maintained in RPMI supplemented with 10% fetal calf serum (FCS), penicillin and streptomycin. 293T cells were cultured in DMEM supplemented with 10% FCS, penicillin and streptomycin. Whilst 293T cells express endogenous APOBEC3C and APOBEC3F (but not APOBEC3G) as judged by RT-PCR, northern blot analysis reveals that the abundance of these transcripts is very low and is augmented several orders of magnitude following transfection. MLV and HIV-1-like viruses were generated using a three-plasmid expression system employing a HIV-1 or MLV shuttle vector, a Gag-Pol expresser and a vector encoding the envelope glycoprotein VSV-G. The self-inactivating HIV-1 packageable vector CSGW encodes eGFP expressed from a SFFV 5'LTR promoter (45,46). HIV-1 Gag-Pol expression plasmids with (p8.2) or without (p8.9) vif were previously described (47). CSGW, p8.2 and p8.9 were generously donated by Greg Towers, Wohl Virion Centre, London, UK. The pVif, pDeltaVif, M5P (MLV packageable genome), pOGP (MLV Gag-Pol expresser) and pMDG (VSV-G) expression vectors were described here (6,16). The pVif vector expresses Vif under the control of a CMV promoter. The pDeltaVif plasmid expresses only the 20 first amino acids of Vif (6).
###end p 13
###begin title 14
Constructs
###end title 14
###begin p 15
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
Generation of vectors coding for eGFP-tagged APOBEC3s is described here (6). A FLAG-tag expression vector was generated by removing the eGFP cassette from the pEGFP-C3 plasmid (Invitrogen) and replacing it by a FLAG sequence at the NheI and ScaI sites. Flag-tagged APOBEC3 expression vectors were generated by subcloning the corresponding APOBEC coding sequence obtained from the pEGFP-APOBEC3G, -APOBEC3F and -APOBEC3C plasmids into the XhoI and PstI sites of the FLAG-tag expression vector. APOBEC3F mutants were made using an embedded and overlapping primer technique. Primer sequences are presented in Table S1.
###end p 15
###begin p 16
###xml 500 506 500 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 548 554 548 554 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
###xml 481 576 481 576 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="17">3C: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGAAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNNN<bold>TCTAGA</bold>TCACTGGAGACTCTCCCG-3&#8242;;</p>
###xml 481 576 481 576 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="17">3C: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGAAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNNN<bold>TCTAGA</bold>TCACTGGAGACTCTCCCG-3&#8242;;</p></list-item>
###xml 596 602 596 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTCGAG</bold>
###xml 644 650 644 650 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 576 674 576 674 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="18">3F1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNNN<bold>GGTACC</bold>TCTGAGAATCTCCTTTAGCG-3&#8242;;</p>
###xml 576 674 576 674 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="18">3F1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNNN<bold>GGTACC</bold>TCTGAGAATCTCCTTTAGCG-3&#8242;;</p></list-item>
###xml 694 700 694 700 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 741 747 741 747 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
###xml 674 772 674 772 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="19">3F2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGGAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCATTCGAGAATCTCCTGCAG-3&#8242;;</p>
###xml 674 772 674 772 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="19">3F2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGGAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCATTCGAGAATCTCCTGCAG-3&#8242;;</p></list-item>
###xml 792 798 792 798 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTCGAG</bold>
###xml 839 845 839 845 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 772 870 772 870 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="20">3G1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>TCTGAGAATCTCCCCCAGCAT-3&#8242;;</p>
###xml 772 870 772 870 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="20">3G1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>TCTGAGAATCTCCCCCAGCAT-3&#8242;;</p></list-item>
###xml 890 896 890 896 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 936 942 936 942 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
###xml 870 967 870 967 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="21">3G2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>CACTCGATGGATCCACCCAC-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCAGTTTTCCTGATTCTGGAG-3&#8242;.</p>
###xml 870 967 870 967 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="21">3G2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>CACTCGATGGATCCACCCAC-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCAGTTTTCCTGATTCTGGAG-3&#8242;.</p></list-item>
###xml 481 967 481 967 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="simple"><list-item><p textid="17">3C: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGAAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNNN<bold>TCTAGA</bold>TCACTGGAGACTCTCCCG-3&#8242;;</p></list-item><list-item><p textid="18">3F1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNNN<bold>GGTACC</bold>TCTGAGAATCTCCTTTAGCG-3&#8242;;</p></list-item><list-item><p textid="19">3F2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>AACCCGATGGAGGCAATGTAT-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCATTCGAGAATCTCCTGCAG-3&#8242;;</p></list-item><list-item><p textid="20">3G1: (F-XhoI) 5&#8242;-NNN<bold>CTCGAG</bold>ATGAAGCCTCACTTCAGAAAC-3&#8242;, (R-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>TCTGAGAATCTCCCCCAGCAT-3&#8242;;</p></list-item><list-item><p textid="21">3G2: (F-KpnI) 5&#8242;-NNN<bold>GGTACC</bold>CACTCGATGGATCCACCCAC-3&#8242;, (R-XbaI) 5&#8242;-NNN<bold>TCTAGA</bold>TCAGTTTTCCTGATTCTGGAG-3&#8242;.</p></list-item></list>
APOBEC3 chimeras were made by PCR amplification of each separate domain of APOBEC3C, APOBEC3F and APOBEC3G, and ligating compatible ends in the pEGFP-C3 vector (Invitrogen). The micro-chimeras (F1-F2a/Cb and F1-Ca/F2b) were generated using an internal BstEII restriction site and exchanging sub-domains between APOBEC3C and APOBEC3F2 (see Figure S1). The primers used to amplify each individual domain and their respective restriction sites are as follows (N represents any base): 3C: (F-KpnI) 5'-NNNGGTACCAACCCGATGAAGGCAATGTAT-3', (R-XbaI) 5'-NNNNTCTAGATCACTGGAGACTCTCCCG-3';3F1: (F-XhoI) 5'-NNNCTCGAGATGAAGCCTCACTTCAGAAAC-3', (R-KpnI) 5'-NNNNGGTACCTCTGAGAATCTCCTTTAGCG-3';3F2: (F-KpnI) 5'-NNNGGTACCAACCCGATGGAGGCAATGTAT-3', (R-XbaI) 5'-NNNTCTAGATCATTCGAGAATCTCCTGCAG-3';3G1: (F-XhoI) 5'-NNNCTCGAGATGAAGCCTCACTTCAGAAAC-3', (R-KpnI) 5'-NNNGGTACCTCTGAGAATCTCCCCCAGCAT-3';3G2: (F-KpnI) 5'-NNNGGTACCCACTCGATGGATCCACCCAC-3', (R-XbaI) 5'-NNNTCTAGATCAGTTTTCCTGATTCTGGAG-3'.
###end p 16
###begin p 17
###xml 19 25 19 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 67 73 67 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
3C: (F-KpnI) 5'-NNNGGTACCAACCCGATGAAGGCAATGTAT-3', (R-XbaI) 5'-NNNNTCTAGATCACTGGAGACTCTCCCG-3';
###end p 17
###begin p 18
###xml 20 26 20 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTCGAG</bold>
###xml 68 74 68 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
3F1: (F-XhoI) 5'-NNNCTCGAGATGAAGCCTCACTTCAGAAAC-3', (R-KpnI) 5'-NNNNGGTACCTCTGAGAATCTCCTTTAGCG-3';
###end p 18
###begin p 19
###xml 20 26 20 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 67 73 67 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
3F2: (F-KpnI) 5'-NNNGGTACCAACCCGATGGAGGCAATGTAT-3', (R-XbaI) 5'-NNNTCTAGATCATTCGAGAATCTCCTGCAG-3';
###end p 19
###begin p 20
###xml 20 26 20 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTCGAG</bold>
###xml 67 73 67 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
3G1: (F-XhoI) 5'-NNNCTCGAGATGAAGCCTCACTTCAGAAAC-3', (R-KpnI) 5'-NNNGGTACCTCTGAGAATCTCCCCCAGCAT-3';
###end p 20
###begin p 21
###xml 20 26 20 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</bold>
###xml 66 72 66 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCTAGA</bold>
3G2: (F-KpnI) 5'-NNNGGTACCCACTCGATGGATCCACCCAC-3', (R-XbaI) 5'-NNNTCTAGATCAGTTTTCCTGATTCTGGAG-3'.
###end p 21
###begin title 22
RT-PCR
###end title 22
###begin p 23
RNA was extracted from CEM or CEM-SS cells using TRIZOL reagent (Gibco) according to the manufacturer's specifications. Ten micrograms of RNA were reverse-transcribed using random hexamers (NEB) and Superscript II reverse transcriptase (Invitrogen). APOBEC3F was amplified using the following primers: (F): 5'-CCTACGCAAAGCCCTATGGTGGAAC-3', (R): 5'-CAGTATGTCGTCACAGAACCAAGAG-3'. APOBEC3G was amplified using these primers: (F): 5'-CCACATAAACACGGTTTCCTTGAAG-3', (R): 5'-CTGACATCTTCCTTGATCATCATAG-3'. These primers are specific for APOBEC3F and APOBEC3G and did not cross-react. APOBEC3C was amplified with the following primers: (F): 5'-GAGGCCACCATGAATCCACAGATCAGAAA-3', (R): 5'-TCCTGGTAACATGGATACTG-3'.
###end p 23
###begin title 24
Generation of virus-like particles
###end title 24
###begin p 25
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
293T cells were co-transfected with Fugene 6 (Roche) at 70% confluence. FLAG- or eGFP-APOBEC encoding plasmids were transfected at a 0.2:1 ratio with respect to CSGW and at a 1:1 ratio with respect of M5P unless otherwise stated. For HIV-1 infectivity assays, cells were co-transfected with CSGW, p8.2 or p8.9 and pMDG at a 1:0.75:0.75 ratio. For MLV production, the cells were transfected with M5P, pOGP and pMDG at a 1:0.70:0.30 ratio. All transfections within the same experiment were made-up to the same amount of total DNA using pcDNA3.1 (Invitrogen). 293T cells were washed the day following transfection with PBS and grown in culture media for 48 h. Virus-containing supernatants were collected 72 h post-transfection and filtered through a 0.45 muM filter.
###end p 25
###begin title 26
Encapsidation
###end title 26
###begin p 27
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
Viruses were produced as described in the previous section by co-transfection of FLAG-APOBEC and virus expression vectors. Supernatants were collected 72 h post-transfection and 293T packaging cells were harvested and assayed for FLAG-APOBEC expression by immunoblot. Virus-containing supernatants were pelleted through a 20% sucrose-PBS solution by ultracentrifugation at 175 000 g in a Beckman TLA-100.4 rotor for 1 h as described elsewhere (9). Virus pellets were solubilized in RIPA buffer containing 0.5% NP-40. Virion and cell lysates were analysed by western blot using a HRP-conjugated anti-FLAG antibody (Sigma).
###end p 27
###begin title 28
Viral sequence analysis
###end title 28
###begin p 29
###xml 321 326 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 515 520 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
293T target cells were collected 48 h post-infection and DNA was extracted using Puregene reagent (Gentra Systems) according to the manufacturer's specifications. DNA preparations were then treated with the restriction endonuclease DpnI to eliminate any trace of plasmid carry-over from the transfection. DNA from MLV or HIV-1 infected cells were amplified using the high fidelity polymerase Pfu turbo (Stratagene) using the following primers MLV: (F): 5'-GGACCATCCTCTAGACTGAAG-3'; (R): 5'-TAATCCGGATCTGTTAACGC-3'; HIV-1: (F): 5'-ATGGTGAGCAAGGGCGAGGAG-3'; (R): 5'-ATCCCGGCGGCGGTCACGAAC-3'. PCR products were then gel purified and cloned using the TOPO-Blunt cloning kit (Invitrogen) and sequenced using M13 reverse primers.
###end p 29
###begin title 30
Southern blot
###end title 30
###begin p 31
###xml 262 264 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
DNA was prepared from target 293T cells as described above. Total DNA was then digested with BamHI and NotI restriction endonucleases and resolved on a 1.2% agarose gel. DNA was then transferred by capillarity to a Hybond N+ nylon membrane and hybridized with a 32P-labeled eGFP cDNA probe for 16 h at 65degreesC. Membranes were washed three times for 30 min in 0.1% SDS, 0.2x SSC and analyzed by phosphorImager.
###end p 31
###begin title 32
Immunoprecipitations and western blots
###end title 32
###begin p 33
###xml 204 210 <span type="species:ncbi:9986">rabbit</span>
For protein analysis, cells were lysed in 10 mM Tris-HCl pH 8, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40 supplemented with protease inhibitors (Roche). EGFP fusion proteins were immunoprecipitated using rabbit anti-GFP (5 mg/ml) (Abcam) together with protein A-Sepharose beads (Amersham). EGFP fusions were visualized by western blot using a HRP-conjugated anti-GFP antibody at a 1:8000 dilution (Abcam), whereas Vif was detected using a 1:1000 dilution of a monoclonal anti-Vif antibody (NIBSC, South Mimms, UK).
###end p 33
###begin title 34
RESULTS
###end title 34
###begin title 35
Anti-retroviral activity of APOBEC3C
###end title 35
###begin p 36
###xml 179 188 179 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 361 376 359 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B and C</xref>
###xml 864 873 862 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
Initial experiments revealed that APOBEC3C (like APOBEC3F and APOBEC3G, but distinct from the related cytidine deaminase AID) could be incorporated into MLV virus-like particles (Figure 1A). This incorporation can indeed have functional implications since APOBEC3C is able to inhibit MLV infection and trigger G-->A mutation of viral replication intermediates (Figure 1B and C). The spectrum of the mutations reveals that the target specificity is distinct from that of both APOBEC3G (which essentially acts only on CC dinucleotides) and APOBEC3F (which essentially acts only on TC dinucleotides): APOBEC3C targets dCs that are preceded by either dC or dT. In contrast, expression of the AID deaminase in these assays gave little anti-viral activity above that of the vector-only control and did not yield any detectable mutation of MLV replication intermediates (Figure 1B, bottom).
###end p 36
###begin p 37
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 915 924 913 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1D</xref>
The precise mechanism by which the APOBEC3 proteins restrict retroviral infectivity under physiological circumstances is uncertain. Various mechanisms have been suggested. These include the possibilities that diminished infectivity is simply a consequence of an excessive mutation load as well as the suggestion that the incorporation of uracil into the retroviral minus-strand cDNA might trigger its destruction (16,48,49). We were therefore interested in ascertaining whether APOBEC3C affected the persistence of viral DNA following infection. Southern blot analysis revealed that all three APOBEC3 members analyzed effected a substantial decrease in the extent of retroviral DNA integration in the infected cells using an MLV-based assay system, although the three deaminases yielded substantially different loadings of G-->A mutation in the retroviral replication intermediates under the same assay conditions (Figure 1D). Although we cannot discriminate whether the viral DNA detected in the Southern blots derives from sequences that have or have not integrated into a host chromosome, the results nevertheless reveal that co-transfection with APOBEC3 plasmids leads to a diminished abundance of retroviral DNA in the target cell, presumably reflecting degradation.
###end p 37
###begin p 38
###xml 465 474 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 710 719 708 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
###xml 926 927 924 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 928 930 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 931 933 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1288 1297 1286 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2C</xref>
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 178 183 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 441 446 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It is clearly interesting to know whether APOBEC3C can also function as a restriction barrier to HIV-1 infection. We find that the APOBEC3C does exert an anti-viral effect in an HIV-1-based assay system (similarly giving rise to G-->A mutation of viral replication intermediates) although APOBEC3C-encoding plasmid is again somewhat less potent than the APOBEC3F/G plasmids. This restriction of infection is at least in part relieved by the HIV-1 Vif gene product (Figure 2A). Furthermore, cytofluorometry experiments performed using cells transfected with plasmids expressing eGFP-tagged APOBEC3C with or without Vif-expressing plasmids indicates that Vif does indeed mediate the destabilization of APOBEC3C (Figure 2B). This destabilization of APOBEC3C by Vif is somewhat surprising in view of the fact that APOBEC3C bears high (81%) homology to the C-terminal domain of APOBEC3F whereas mutational/homology considerations (7-10,34) make it likely that it is the N-terminal domain of APOBEC3F (to which APOBEC3C shows only 53% homology) that interacts with Vif. In order to ascertain whether the Vif-mediated destabilization does indeed correlate with a Vif-APOBEC3C interaction, we performed immunoprecipitation experiments. An interaction can indeed be seen between the two proteins (Figure 2C).
###end p 38
###begin p 39
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 512 513 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 694 703 686 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2D</xref>
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 237 242 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 399 404 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
If restriction of HIV-1 infection by endogenous (as opposed to transfected and over-expressed) APOBEC3C also applies in vivo, then one might expect APOBEC3C not to be expressed in cell-lines that are permissive for infection by Deltavif HIV-1 particles. Indeed, the original discovery that an APOBEC3 family member acted as retroviral restriction elements was based on the observation that Deltavif HIV-1 can be propagated in CEM-SS cells (a permissive T-cell line) but not in the non-permissive CEM progenitor (1). RT-PCR analysis reveals that APOBEC3C, APOBEC3F and APOBEC3G are all expressed in CEM cells but that the expression of all three of them is indeed lost in the CEM-SS derivative (Figure 2D).
###end p 39
###begin title 40
The second domain of APOBEC3F and of APOBEC3G encode the elements responsible for deamination specificity
###end title 40
###begin p 41
###xml 908 917 908 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A</xref>
###xml 979 988 979 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3B</xref>
###xml 1181 1190 1181 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
Since it is the second domain of APOBEC3F that is homologous to the single-domained APOBEC3C, we wondered if the catalytic specificity of APOBEC3F resided in its second domain. One way to approach this issue (as it has been performed with APOBEC3G) is to analyse whether mutations likely to affect zinc coordination by either of the two domains affects its catalytic activity. However, a problem with such an approach is that retention of activity could mean that the catalytic domain in question had not been inactivated; loss of activity could be through general protein destabilization or degradation. Therefore, in view of the fact that APOBEC3C, APOBEC3F and APOBEC3G all exhibit different target specificities, we asked whether replacing the second domain of APOBEC3F by that of APOBEC3G or by APOBEC3C could alter the target specificity of APOBEC3F. All chimeras were readily expressed in 293T cells (Figure 3A) and gave similar inhibition of viral infection as APOBEC3C (Figure 3B and Table S2). The results on DNA deamination were straightforward. The target specificities of the resultant double-domained APOBEC3 chimeras all accorded with that of the C-terminal domain (Figure 3C).
###end p 41
###begin title 42
An APOBEC3F second domain/APOBEC3C chimera yields a novel target specificity
###end title 42
###begin p 43
###xml 645 654 645 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3D</xref>
In order to further dissect the parts of the second domain of APOBEC3F that mediate target specificity, we generated variants of ABOPEC3F (designated F1-Ca/F2b and F1-F2a/Cb, respectively) in which the N- or C-terminal halves of the APOBEC3F second domain were substituted by corresponding portions from APOBEC3C. To our surprise, whilst both chimeras were active in restricting MLV infection, they yielded a mutation spectrum that was quite distinct from both the APOBEC3F and APOBEC3C parents. They both exhibited a strong bias for a C at position -1 (similar, although not quite as marked in extent, to the preference displayed by APOBEC3G) (Figure 3D and Table S2).
###end p 43
###begin title 44
Effects of single amino acid substitutions in the second domain of APOBEC3F on target specificity
###end title 44
###begin p 45
###xml 222 231 222 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 521 522 521 522 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 564 565 564 565 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 797 806 797 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
In order to gain more insight into the molecular basis of the target site specificity of the APOBEC3 deaminases, we tested the effects on specificity of single amino acid substitution in the C-terminal domain of APOBEC3F (Figure 4A and Table S3). The nature of the mutations made was guided by a comparison of the sequence of APOBEC3C with that of APOBEC3F. Thus, mutations were made in residues that differed between APOBEC3F and APOBEC3C, so as to identify those that could be responsible for a shift from the typical TC deamination spectrum of APOBEC3F to the YC spectrum of APOBEC3C. Of the 12 single amino-acid substitutions tested, only APOBEC3F mutant 7 substantially altered the deaminated spectrum at -1, whilst mutants 6 and 9 both gave some modification to the spectrum at position -2 (Figure 4B and Table S3).
###end p 45
###begin title 46
DISCUSSION
###end title 46
###begin p 47
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 133 138 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 402 407 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 633 636 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
The results of this study clearly reveal that APOBEC3C can work on both MLV and HIV-1. An antiviral effect of APOBEC3C on MLV and/or HIV-1 is in fact apparent in several (but not all) previous studies (28-30,33). Whilst differences in the assay systems and retroviral substrates used in the various studies might be a major contributing factor, we suspect that the activity of APOBEC3C against MLV and HIV-1 has not been previously highlighted because it is evidently less potent against these retroviruses than are APOBEC3F and APOBEC3G. Strikingly, in a recent study, Yu et al. (29) have noted that APOBEC3C is very potent against SIV.
###end p 47
###begin p 48
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 459 464 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The in vitro results do not, of course, prove that APOBEC3C acts as a viral restriction element in vivo. This is a difficult issue to address by asking whether APOBEC3C leaves a footprint on the mutation spectrum of naturally occurring hypermutated HIV-1 sequences since the target specificity of APOBEC3C is likely to show some overlap with that of APOBEC3F. However, it is notable that co-transfection with Vif can overcome APOBEC3C-mediated restriction of HIV-1 (29) and, as we show here, Vif and APOBEC3C can partake in an interaction that correlates with APOBEC3C degradation. This is somewhat remarkable in light of the fact that, at least in the case of APOBEC3G, distinct domains seem to be largely responsible for Vif binding and for dominant catalytic activity [(6-10) and see below].
###end p 48
###begin p 49
###xml 577 579 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 580 582 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 617 622 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 625 627 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 774 779 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 803 805 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 482 485 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 666 669 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 796 801 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Despite inducing mutations at a frequency several-fold lower than APOBEC3G or APOBEC3F, APOBEC3C is still capable of inhibiting viral infection and blocking viral DNA persistence in the target cells. The precise mechanism by which APOBEC3 proteins inhibit retroviral infection is not known, but it is possible that the extent of inhibition of retroviral integration does not correlate simply with the extent of retroviral deamination. Interestingly, although G-->A mutations in the HBV genome have been observed in certain experimental conditions and also in clinical samples (50,51), it has been proposed by Turelli et al. (52) that APOBEC3G-mediated inhibition of HBV infection could be independent of deamination. Somewhat analogous observations have been made by Newman et al. with regard to HIV-1 (53). These results hint that there may be other (not deamination-based) mechanisms by which APOBEC3 proteins hinder viral infection.
###end p 49
###begin p 50
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 353 358 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 361 363 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 519 520 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 810 812 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 813 815 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 816 818 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
It has been somewhat unclear as to whether catalytic activity is contained within either or both the domains of the double-domained deaminases (17,20,44). In studies of APOBEC3G, several single or double amino acid substitutions have been found to lead to diminished accumulation of G-->A mutations in the retroviral target although, as noted by Shindo et al. (44), this diminished activity can often be correlated with diminished protein stability, in particular when working with truncated forms of these deaminases (6). Interestingly, however, none of the amino acid substitutions generated in APOBEC3G to date have been found to be sufficient to destroy all deaminating activity although mutations within the catalytic site of the second domain were found to lead to a complete loss of antiviral activity (17,20,44). Here, we have investigated the target site specificities of various chimeric APOBEC3s in order to identify which parts of the proteins are implicated in catalytic activity. The results reveal that the second domain of APOBEC3F and APOBEC3G play a critical role in determining the target specificity of these deaminases with regards to sensitivity to 5'-flanking nucleotides. It is difficult to imagine any interpretation other than that these domains are catalytically active, although we obviously cannot exclude the possibility that the N-terminal domains of these deaminases also exhibit some (but probably much lesser) activity. [During the course of this work, we also generated chimeras in which the N-terminal domain of APOBEC3G was fused with the C-terminal domain of APOBEC3F or with APOBEC3C, but these proteins turned out to be unstable (data not shown) and therefore gave no insight into the possible catalytic activity of the N-terminal domains.]
###end p 50
###begin p 51
We also generated deaminases carrying a chimeric C-terminal domain composed of part APOBEC3C and part APOBEC3F-second domain in order to gain insight into the different target site preferences conferred by these two domains. To our surprise, the hybrids exhibited a target specificity closer to that of APOBEC3G than that of either parent. Furthermore, analysis of APOBEC3F point mutants reveal that sensitivity to 5'-flanking nucleotides can be modified by distinct single amino acid substitutions. Whilst a definitive interpretation of these mutations must await the elucidation of the three-dimensional structure of APOBEC3 deaminases, the results demonstrate that target site preference can be easily perturbed and strongly suggest that this preference must be sensitive to relatively subtle changes in deaminase structure.
###end p 51
###begin p 52
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
It is striking that all four antiviral APOBEC3 deaminases (APOBEC3B, -3C, -3F and 3G) that have been characterized to date display different DNA target site specificities. The precise significance of retroviral deamination to the physiological functioning of the APOBEC3 proteins is still uncertain. It is therefore difficult to know whether the differing target site preferences of the various APOBEC3 proteins reflect differences that were selected during evolution because the local targeting of deamination is intimately associated with the functioning of these proteins in restricting viral infection (35,54). An alternative possibility, given the ease with which the target site preference is perturbed, is that the differing mutational specificities of these proteins are incidental by-products of changes, possibly located outside the immediate vicinity of the active site, that have been selected for other reasons (e.g. a modulation of protein-protein interactions so as to avoid viral counter-measures).
###end p 52
###begin p 53
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">57</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
It is interesting in this context to compare the target site preference of the APOBEC3 proteins to that of AID (activation-induced deaminase) which functions in the adaptive immune system to trigger antibody gene diversification (55,56). AID has a quite distinct target site preference from the APOBEC3 proteins, preferring a purine upstream of the targeted dC (57-59). The deamination preference of AID will presumably have co-evolved with the sequences of its physiological targets (the variable and switch regions of the immunoglobulin loci) so as to allow both optimal targeting of somatic mutations during antibody affinity maturation and efficient class switch recombination (60,61). The structural basis for major difference in target specificity of AID and APOBEC3 proteins is currently unknown. Strikingly, in a recent mutagenesis study of AID, Bransteitter et al. (62) have similarly concluded that a single amino acid substitution outside the catalytic site (in fact located in the N-terminal region of this protein) can affect mutational specificity.
###end p 53
###begin p 54
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">63</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">65</xref>
###xml 491 499 491 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Both this study and that of Bransteitter et al. (62) reveal that it is relatively easy to generate altered AID/APOBEC family deaminases that exhibit novel mutational specificities. AID-mediated DNA deamination not only underpins the physiological mechanism of antibody affinity maturation, it also underpins several in vitro strategies that exploit an iterative alternation of mutation and selection to derive proteins with desired characteristics (63-65). The functional diversity in these in vitro systems is significantly restricted by the limited mutational specificity of the DNA deaminase: generating a range of deaminases with differing (and possibly more relaxed) target specificities could therefore prove of some utility.
###end p 54
###begin title 55
SUPPLEMENTARY MATERIAL
###end title 55
###begin p 56
Supplementary Material is available at NAR Online.
###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
[Supplementary Material]
###end title 58
###begin p 59
We thank the Centralized Facility for AIDS Reagents for monoclonal anti-Vif antibodies and the NIBSC for providing the CEM-SS cell line. We also thank Christina Rada for helpful discussions and experimental advice. This work was supported by a grant from the Leukaemia Research Fund to M.S.N. M.A.L. is a recipient of a postdoctoral fellowship award from the Fond de Recherche en Sante du Quebec (FRSQ). S.G.C. was supported by a Marie Curie Fellowship of the European Community programme FP5 under contract number MCFI-2002-01357. Funding to pay the Open Access publication charges for this article was provided by the UK Medical Research Council.
###end p 59
###begin p 60
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 60
###begin title 61
REFERENCES
###end title 61
###begin article-title 62
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
###end article-title 64
###begin article-title 65
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
###end article-title 65
###begin article-title 66
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
###end article-title 66
###begin article-title 67
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G
###end article-title 67
###begin article-title 68
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)
###end article-title 68
###begin article-title 69
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
###end article-title 69
###begin article-title 70
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor
###end article-title 70
###begin article-title 71
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action
###end article-title 71
###begin article-title 72
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein
###end article-title 72
###begin article-title 73
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction between HIV-1 Gag and APOBEC3G
###end article-title 73
###begin article-title 74
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles
###end article-title 74
###begin article-title 75
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging
###end article-title 75
###begin article-title 76
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor
###end article-title 76
###begin article-title 77
DNA deamination mediates innate immunity to retroviral infection
###end article-title 77
###begin article-title 78
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
###end article-title 78
###begin article-title 79
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome
###end article-title 79
###begin article-title 80
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein
###end article-title 80
###begin article-title 81
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
###end article-title 81
###begin article-title 82
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators
###end article-title 82
###begin article-title 83
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
###end article-title 83
###begin article-title 84
###xml 52 87 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Selection, recombination, and G->A hypermutation of human immunodeficiency virus type 1 genomes
###end article-title 84
###begin article-title 85
###xml 43 71 <span type="species:ncbi:12721">human immunodeficiency virus</span>
A new type of G->A hypermutation affecting human immunodeficiency virus
###end article-title 85
###begin article-title 86
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G->A hypermutation during negative-strand viral DNA synthesis
###end article-title 86
###begin article-title 87
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells
###end article-title 87
###begin article-title 88
###xml 71 106 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Sustained G->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome
###end article-title 88
###begin article-title 89
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication
###end article-title 89
###begin article-title 90
###xml 47 76 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication
###end article-title 90
###begin article-title 91
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins
###end article-title 91
###begin article-title 92
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo
###end article-title 92
###begin article-title 93
###xml 25 54 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
Further investigation of simian immunodeficiency virus Vif function in human cells
###end article-title 93
###begin article-title 94
Cytidine deamination of retroviral DNA by diverse APOBEC proteins
###end article-title 94
###begin article-title 95
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22
###end article-title 95
###begin article-title 96
Rapid evolution of primate antiviral enzyme APOBEC3G
###end article-title 96
###begin article-title 97
Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases
###end article-title 97
###begin article-title 98
Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business
###end article-title 98
###begin article-title 99
###xml 31 37 <span type="species:ncbi:9986">rabbit</span>
Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed
###end article-title 99
###begin article-title 100
Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site
###end article-title 100
###begin article-title 101
Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity
###end article-title 101
###begin article-title 102
Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex
###end article-title 102
###begin article-title 103
###xml 25 36 25 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. subtilis</italic>
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 25 36 <span type="species:ncbi:428509|species:ncbi:1423|species:ncbi:518697">B. subtilis</span>
###xml 41 48 <span type="species:ncbi:562">E. coli</span>
Cytidine deaminases from B. subtilis and E. coli: compensating effects of changing zinc coordination and quaternary structure
###end article-title 103
###begin article-title 104
###xml 17 33 17 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 17 33 <span type="species:ncbi:562">Escherichia coli</span>
The structure of Escherichia coli cytosine deaminase
###end article-title 104
###begin article-title 105
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity
###end article-title 105
###begin article-title 106
###xml 88 123 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter
###end article-title 106
###begin article-title 107
Restriction of lentivirus in monkeys
###end article-title 107
###begin article-title 108
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
###end article-title 108
###begin article-title 109
Good to CU
###end article-title 109
###begin article-title 110
Death and the retrovirus
###end article-title 110
###begin article-title 111
###xml 24 41 <span type="species:ncbi:10407">hepatitis B virus</span>
G to A hypermutation of hepatitis B virus
###end article-title 111
###begin article-title 112
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Comment on 'Inhibition of hepatitis B virus replication by APOBEC3G'
###end article-title 112
###begin article-title 113
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G
###end article-title 113
###begin article-title 114
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity
###end article-title 114
###begin article-title 115
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G
###end article-title 115
###begin article-title 116
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme
###end article-title 116
###begin article-title 117
Immunity through DNA deamination
###end article-title 117
###begin article-title 118
Transcription-targeted DNA deamination by the AID antibody diversification enzyme
###end article-title 118
###begin article-title 119
Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation
###end article-title 119
###begin article-title 120
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo
###end article-title 120
###begin article-title 121
An evolutionarily conserved target motif for immunoglobulin class-switch recombination
###end article-title 121
###begin article-title 122
Codon bias targets mutation
###end article-title 122
###begin article-title 123
Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase
###end article-title 123
###begin article-title 124
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines
###end article-title 124
###begin article-title 125
Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas
###end article-title 125
###begin article-title 126
Evolution of new nonantibody proteins via iterative somatic hypermutation
###end article-title 126
###begin title 127
Figures and Tables
###end title 127
###begin p 128
###xml 48 49 48 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 586 587 586 587 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1411 1412 1411 1412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1939 1940 1935 1936 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
APOBEC3C has an anti-retroviral effect on MLV. (A) APOBEC3 proteins but not AID or U2AF are packaged in MLV virus-like particles. Virions were produced by co-transfection of 293T cells with M5p, Gag-Pol, VSV-G and Flag-tagged APOBEC expression vectors. Three days after transfection, viruses were isolated from the supernatant by ultracentrifugation and producer cells were collected. Viral pellet and producer cells were then lysed and submitted to western blot analysis using anti-FLAG HRP-conjugated monoclonal antibody. Sample loading was controlled using an anti-p30gag antibody. (B) Upper panel: inhibition of MLV infection by various AID or APOBEC3 proteins. 293T cells were co-transfected with MLV producer plasmids in combinations with either of the FLAG-tagged APOBEC3 or of the AID expression plasmids. Expression of eGFP was measured 48 h later by FACS analysis. Histograms represent the mean of at least three independent experiments and error bars represent the corresponding standard error. Lower panel: titration effect of various FLAG-tag APOBEC3 proteins on MLV infectivity. Increasing APOBEC3/AID:M5P ratios were used to co-transfect 293T cell. Only the amount of APOBEC3/AID plasmid was modified and the total amount of DNA was adjusted with empty pCDNA3.1 vector. EGFP expression was monitored by FACS 48 h post-infection. Each point represents the average of two independent experiments. (C) Upper panel: mutation analysis of the MLV-encoded eGFP gene that successfully integrated into the genome of 293T target cells. Viruses were produced in the presence of APOBEC3C, APOBEC3F or APOBEC3G. Numbers correspond to the frequency in percentage at which the adjacent bases are represented in the mutated sequences. 'n' represents the number of independent G-->A mutations. Lower panel: sequences of the eGFP gene of MLV amplified from 293T target cells. Vertical lines depict the relative locations of G-->A mutations. (D) APOBEC3C, APOBEC3F and APOBEC3G inhibit viral genome integration in target 293T cells. DNA was extracted from 293T cells infected with MLV virus-like particles, digested and a Southern blot analysis was performed using an eGFP cDNA probe to detect viral DNA sequences and a genomic APOBEC2 probe for sample normalization. The ethidium bromide-stained gel before DNA transfer is also shown.
###end p 128
###begin p 129
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 693 694 681 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 972 973 956 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1010 1011 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1018 1019 1002 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1031 1032 1015 1016 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1424 1425 1408 1409 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 18 21 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 87 92 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 186 191 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 195 200 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 524 529 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3C inhibits HIV infection and is sensitive to Vif. (A) Left panel: inhibition of HIV-1 and HIV-1 (Deltavif) by various AID or APOBEC3 proteins. 293T cells were co-transfected with HIV-1 or HIV-1 (Deltavif) producer plasmids in combinations with either of the FLAG-tagged APOBEC3 or of the AID expression plasmids. Histograms represent the mean of at least three independent experiments and error bars represent the corresponding standard error. Right panel: titration effect of various FLAG-tagged APOBEC3 proteins on HIV-1 (Deltavif) infectivity. Increasing APOBEC3/AID:CSGW ratios were used to co-transfect 293T cell. Each point represents the average of two independent experiments. (B) 293T cells were co-transfected with peGFP-C3, eGFP-APOBEC3C or eGFP-APOBEC3G and plasmids expressing either Vif or DeltaVif (Ctrl). Fluorescence was monitored for 5 days by FACS analysis. Each point represents the average and standard error of three independent measurements. *Significantly different by Student's t-test (P = 0.007). (C) 293T cells were co-transfected with pVif alone (Ctrl) or pVif and peGFP-C3, eGFP-APOBEC3C or eGFP-APOBEC3G, and cell lysates were prepared 48 h later. The bulk of the lysate was submitted to immunoprecipitation with an anti-eGFP monoclonal antibody. Immunoprecipitates and cell lysates were then submitted to SDS-PAGE and the western blots were probed with anti-Vif monoclonal antibodies. (D) Expression of APOBEC3C, APOBEC3F and APOBEC3G in CEM and CEM-SS cells. An RT-PCR was performed on RNA isolated from either CEM (upper panel) or CEM-SS (lower panel). Results reveal that the CEM-SS clone has lost the expression of APOBEC3C, -3F and -3G.
###end p 129
###begin p 130
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 246 247 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 457 458 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 463 464 463 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
The second domain of APOBEC3F and APOBEC3G enclose the elements governing deamination spectrum specificity. (A) Western blot analysis of the different chimeric APOBEC3 proteins. An HRP-conjugated anti-eGFP antibody was used to reveal the bands. (B) F1C and F1G2 chimeric APOBEC3 proteins show a strong antiviral effect on MLV virus-like particles. Histograms represent the mean of three independent experiments and error bars represent the standard error. (C and D) Schematic representation of the different chimeric APOBEC3F proteins and their respective deamination spectrum at positions -2 and -1 in relation to the deaminated dC is depicted in pie charts. 'n' represents the number of independent G-->A mutations.
###end p 130
###begin p 131
###xml 85 86 85 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 244 245 244 245 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
The deamination spectrum of APOBEC3F is altered by single amino acid substitutions. (A) Sequence alignment of APOBEC3C and the second domain of APOBEC3F. Numbers indicate residues that were changed to generate the 12 mutant APOBEC3F proteins. (B) Histograms depicting the proportion of each nucleotide at positions -2 and -1 in relation to the deaminated dC.
###end p 131

